» Authors » Andrew J Wiemer

Andrew J Wiemer

Explore the profile of Andrew J Wiemer including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 59
Citations 974
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Nguyen K, Hsiao C, Jin Y, Wiemer A, Vinogradova O
FASEB J . 2025 Mar; 39(6):e70449. PMID: 40079188
Butyrophilin 3A1 (BTN3A1) is an integral membrane protein capable of detecting phosphoantigens, like (E)-4-hydroxy-3-methyl-but-2-enyl diphosphate (HMBPP), through its internal B30.2 domain. Detection of phosphoantigens leads to interactions with butyrophilin 2A1...
2.
Huang X, Pawge G, Snicer C, Hsiao C, Wiemer A
J Immunol . 2025 Mar; 214(1):55-71. PMID: 40073261
Poliovirus receptor (PVR) ligands have gained attention as immunotherapy targets, yet their regulation remains unclear. Here, we examine the impact of PVR exposure on primary human CD8+ T cells. We...
3.
Singh U, Pawge G, Kintigh P, Sarno J, Rani S, Hsiao C, et al.
Eur J Med Chem . 2025 Feb; 287:117345. PMID: 39919440
The most effective natural ligand for the butyrophilins is (E)-4-hydroxy-3-methyl-but-2-enyl diphosphate. However, due to its susceptibility to plasma hydrolysis and its high charge that limits passive diffusion across cell membranes,...
4.
Singh U, Pawge G, Rani S, Hsiao C, Wiemer D, Wiemer A
ACS Med Chem Lett . 2024 Oct; 15(10):1771-1777. PMID: 39411535
While ester-based phosphonate prodrugs excel at delivering payloads into cells, their instability in plasma is a hurdle for their advancement. Here, we synthesized new aryl/acyloxy prodrugs of a phosphonate BTN3A1...
5.
Singh R, Rani S, Jin Y, Hsiao C, Wiemer A
Eur J Med Chem . 2024 Jul; 276:116673. PMID: 39029338
Phosphoantigens (pAgs) induce conformational changes after binding to the intracellular region of BTN3A1 which result in its clustering with BTN2A1, forming an activating ligand for the Vγ9Vδ2 T cell receptor....
6.
Lami I, Wiemer A
Drugs R D . 2024 Jul; 24(2):129-144. PMID: 38951479
Melanoma is an aggressive, rapidly developing form of skin cancer that affects about 22 per 100,000 individuals. Treatment options for melanoma patients are limited and typically involve surgical excision of...
7.
Karunakaran M, Subramanian H, Jin Y, Mohammed F, Kimmel B, Juraske C, et al.
Nat Commun . 2023 Nov; 14(1):7617. PMID: 37993425
Butyrophilin (BTN)-3A and BTN2A1 molecules control the activation of human Vγ9Vδ2 T cells during T cell receptor (TCR)-mediated sensing of phosphoantigens (PAg) derived from microbes and tumors. However, the molecular...
8.
Singh U, Pawge G, Rani S, Hsiao C, Wiemer A, Wiemer D
J Med Chem . 2023 Nov; 66(22):15309-15325. PMID: 37934915
Activation of Vγ9Vδ2 T cells with butyrophilin 3A1 (BTN3A1) agonists such as ()-4-hydroxy-3-methyl-but-2-enyl diphosphate (HMBPP) has the potential to boost the immune response. Because HMBPP is highly charged and metabolically...
9.
Nguyen K, Jin Y, Howell M, Hsiao C, Wiemer A, Vinogradova O
J Immunol . 2023 May; 211(1):23-33. PMID: 37171180
Intracellular binding of small-molecule phospho-Ags to the HMBPP receptor complex in infected cells leads to extracellular detection by T cells expressing the Vγ9Vδ2 TCR, a noncanonical method of Ag detection....
10.
Karunakaran M, Subramanian H, Jin Y, Mohammed F, Kimmel B, Juraske C, et al.
Res Sq . 2023 Feb; PMID: 36824912
Butyrophilin (BTN)-3A and BTN2A1 molecules control TCR-mediated activation of human Vγ9Vδ2 T-cells triggered by phosphoantigens (PAg) from microbes and tumors, but the molecular rules governing antigen sensing are unknown. Here...